ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, Cristiana Sessa, Andreas du Bois et al.|Annals of Oncology|2019Cited by 1.2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Michael Friedländer et al.|The Lancet Oncology|2021Cited by 412
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Domenica Lorusso et al.|The Lancet Oncology|2021Cited by 148
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trialOlivier Mir, Étienne Minvielle, Marie Ferrua et al.|Nature Medicine|2022Cited by 138
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryPatricia Pautier, Florence Duffaud|ESMO Open|2021Cited by 27